• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

COVID-19 Convalescent Plasma Improves Outcomes for Cancer Patients

January 10, 2023

Standard COVID-19 therapies and vaccines have limited effectiveness in patients with impaired humoral immune responses, and these patients have a high risk of severe COVID-19.  High titer COVID-19 convalescent plasma (CCP) used early in the disease has been shown to reduce the risk of hospitalization among immunocompetent outpatients. A new randomized clinical trial from Germany supports CCP use in patients with cancer.  From September 2020 to January 2022, 134 high risk patients with PCR-confirmed SARS-CoV-2 infections (mean age=69 years, 32.1% female, 11.2% fully vaccinated) were randomized to receive either standard care (n=66) or standard care in addition to two units of ABO-compatible, high titer CCP (titers >1:80) (n=68) on the day of randomization (average of 7 days after symptom onset).  Four high-risk groups were evaluated:  1) cancer (n=56, hematologic and solid); 2) immunosuppression (n=16); 3) lymphopenia/elevated D-dimers (n=36); 4) age>75 years (n=26).  Although no differences in outcomes were seen when all the risk-groups were combined, patients with cancer who received CCP improved more quickly (HR=2.50; P=0.003) and had increased survival compared to the control arm (HR=0.28; P=0.42).  Unlike monoclonal antibodies and vaccines, convalescent plasma, has the potential to evolve in real-time with the virus and may be an important component of treating patients with cancer and COVID-19.

Reference:

Denkinger, C.M., Janssen, M., Schäkel, U. et al. Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial. Nat Cancer (2022).

Filed Under

  • Coagulation & Plasma Transfusion
  • News

Recommended

  • Restrictive or Liberal Transfusion Thresholds for Patients with Myocardial Infarctions

  • Intravenous Immunoglobulin Treatment for Patients with Heparin-Induced Thrombocytopenia Patients Unresponsive to Standard Treatment

  • Feasibility of Post-donation Iron Replacement for Whole Blood Donors

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • New Erythropoietin Gene Variants Linked to Hereditary Erythrocytosis

  • Multifaceted Threats to the Blood Supply from Climate Change

  • Distinct Roles for Differently Aged Platelets

  • Anemia Treatment Bundle Improves Hemoglobin Recovery after Critical Illness

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley